Company Filing History:
Years Active: 2015-2017
Title: Roni Mintz: Innovator in Immunology
Introduction
Roni Mintz is a notable inventor based in Moshav Shafir, Israel. He has made significant contributions to the field of immunology, holding a total of four patents. His work focuses on developing innovative solutions that enhance the understanding and treatment of thrombotic conditions.
Latest Patents
One of Roni Mintz's latest patents is titled "Immunoglobulin reduced in thrombogenic agents and preparation thereof." This invention relates to an immunoglobulin composition that is reduced in thrombogenic agents, along with methods for its preparation. One method involves subjecting an immunoglobulin-containing solution to negative cation exchanger chromatography at a pH range of higher than 3.8 to equal to or lower than 5.3. Additionally, the solution can be subjected to negative anion exchanger chromatography at a pH range of 7 to 8.2. Another significant patent is the "Immunoassay for thrombin detection." This invention provides an in vitro immunoassay for quantifying thrombin in a sample, which includes anti-thrombin III (AT-III) and thrombin. The method consists of several steps, including contacting the sample with a small molecule that recognizes the substrate binding site of thrombin and measuring the level of bound antibody.
Career Highlights
Roni Mintz has established himself as a key figure in the biopharmaceutical industry. He works at Omrix Biopharmaceuticals Inc., where he continues to innovate and develop new therapeutic solutions. His expertise in immunology has led to advancements that benefit both research and clinical applications.
Collaborations
Roni Mintz collaborates with talented professionals in his field, including Israel Nur and Oleg Belyaev. These partnerships enhance the research and development efforts at Omrix Biopharmaceuticals Inc.
Conclusion
Roni Mintz is a distinguished inventor whose work in immunology has led to valuable patents and advancements in the field. His contributions continue to impact the biopharmaceutical industry positively.